Adicet Bio says prula-cel Phase 1 lupus study shows 54% DORIS remission at 12 months

• Adicet Bio reported updated Phase 1 data for prula-cel in systemic lupus erythematosus, including patients with lupus nephritis.
• Results were released now, with an investor webcast scheduled for today.
• Patients showed sustained disease control with many reaching remission, alongside broad discontinuation of immunosuppressants and meaningful steroid tapering.
• Safety looked manageable, supporting outpatient use, with no severe cytokine release syndrome or serious neurologic immune-related events reported.
• Start-up activities for a single-arm pivotal lupus nephritis study are planned for 4Q/2026, with possible expansion into non-renal lupus.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adicet Bio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609280645BIZWIRE_USPR_____20260928_BW907981) on September 28, 2026, and is solely responsible for the information contained therein.